Imatinib Therapy - GIST. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Imatinib Therapy - GIST, 2025, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6727/335_v4_Imatinib.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).	1
Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
HSE (2)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib